Loading...
XSTO
IZAFE B
Market cap19mUSD
Dec 05, Last price  
0.59SEK
1D
7.27%
1Q
63.43%
Jan 2017
-92.53%
IPO
-78.15%
Name

iZafe Group AB

Chart & Performance

D1W1MN
XSTO:IZAFE B chart
P/E
P/S
23.04
EPS
Div Yield, %
Shrs. gr., 5y
66.64%
Rev. gr., 5y
-11.10%
Revenues
8m
+336.55%
3,75026,41939,1015,698000155,0007,571,00014,328,0008,904,000442,000729,0001,822,0007,954,000
Net income
-21m
L-36.26%
-5,907,245-4,941,580-2,917,935-7,228,886-3,170,867-2,596,712-6,356,026-4,269,000-11,312,000-23,116,000-12,754,000-39,277,000-23,526,000-32,174,999-20,509,000
CFO
-11m
L+0.88%
-1,621,933-941,317-829,552-1,772,786-4,316,036-3,719,000-1,410,000-15,319,000-24,567,000-33,493,000-21,457,000-11,256,000-11,355,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

iZafe Group AB (publ), a life-science company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated drug dispenser that handles dose bags, facilitates and enables independent medication, and reminds and alerts if the current dose is not taken at the right time. It serves consumers, and public and private-sector care providers in Sweden, the Nordic region, and internationally. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.
IPO date
Apr 04, 2011
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT